Moderna has touted the possibility of an accelerated approval for its Merck-partnered cancer vaccine by 2025. But according to executives, three things need to happen first. Merck and Moderna made news in December 2022 when they unveiled Phase II data suggesting their...
Degrader-antibody conjugates (DACs) have emerged as an innovative approach for the targeted delivery of chemotherapeutics, offering the potential for more efficient and precise cancer treatment. Clinical trials for DACs have recently begun, signaling advancement in...
Eli Lilly and Company, a leading pharmaceutical giant based in Indianapolis, has announced the termination of a Phase III clinical trial for its cancer drug Verzenio in the treatment of metastatic castration-resistant prostate cancer (mCRPC). The decision came after...
Researchers at Cincinnati Children’s outlined two workflows for detecting new targets for cancer immunotherapies, one based on T cell antigens, the other upon B cell antigens. Credit: Cincinnati Children’s An innovative computational tool dubbed...
